Every letter we have printed

Labelling the date of reconstitution on the vial is the single practice that would improve this most, and it requires a marker pen. Half the uncertainty in these discussions is uncertainty about how long something has been sitting.

You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.

Diode-array spectra are the single most under-used piece of data in this trade. The instrument collects them whether or not anybody looks, and the file is already on the disk. Asking a laboratory to include a spectral homogeneity check costs an analyst five minutes and answers a question the percentage cannot.

A note on detector linearity, which the article passes over. Above a certain injected mass the response stops being proportional, and the main peak reaches that ceiling long before the impurities do. An overloaded injection therefore flatters the impurities rather than the product, which is the opposite of what most readers assume.

A small practical note. Ask for the suitability summary at the time of ordering rather than afterwards. Requested up front it is a checkbox; requested afterwards it looks like a challenge, and the correspondence takes three weeks instead of an afternoon.

Acting on your section about system suitability, I asked a laboratory whether the criteria had been met on my run. They sent the suitability summary the same afternoon, unprompted and without charge, and it showed a tailing factor of 1.3 and replicate agreement well inside a per cent. Nothing was being withheld. Nobody had ever asked.

The run-in and titration phases are where most of the reported events occur and where the fewest measurements are taken. It is an understandable design choice and it means the noisiest period is also the least documented.

The phrase dose-limiting has a precise meaning in trial design and a loose one everywhere else. In a protocol it names the point at which escalation stops; in general use it names discomfort. The two are frequently conflated in coverage of the same study.

Time is the variable custody records exist to capture, and almost every account I read gives dates rather than durations. Eleven days between purchase and injection is a fact about the result; the two dates it is derived from are usually printed and never subtracted.

I would like to see the phrase used more carefully in this publication as well. Where the history is a courier number and a photograph, say so. Where it is a signed transfer record, say that. The reader can weigh either if they are told which they are reading.

Credit where it is due: all four answered your questionnaire and answered it on the record. In my experience of trying to get straight answers out of laboratories in other sectors, that is not the normal outcome, and it says something about how these organisations see their role.

A blind purchase can still be detected. Unusual delivery addresses, first-time customers ordering a single unit of an unusual line, payment methods that stand out — a supplier paying attention has several signals available, and none of them require anybody to behave badly.

The spread you reported is, by the standards of interlaboratory comparison in sectors I have worked in, unremarkable. That is not a criticism of your reporting; it is a correction to the alarm some readers will take from it. Two laboratories differing by a point on a chromatographic purity are behaving normally.

Nobody has defined what custody means in a market where the buyer is an individual and the laboratory is on another continent. Importing the phrase from clinical practice without importing the institutions has produced a word with no local meaning.

We ask customers to send the vial unopened and we record the seal condition on arrival. It has produced two useful findings in three years, both about transit rather than about the supplier, and neither would have been visible if the sample had arrived as a powder in a bag.

Treating the four services as institutions rather than as brands is the right frame and it exposes how thin the institutional layer is. Four organisations, no common reporting standard, no shared reference material and no mechanism by which one can be compared with another except by a buyer paying twice.

A general point about rate. Everything here is kinetics, not thresholds, and the popular framing of a material being fine until it suddenly is not has no basis in the chemistry. Loss is continuous and the question is how much.

Hydrolysis at the peptide bond is slow at refrigerated temperatures and not at room temperature, and the difference across that range is much larger than people assume from the small numerical gap.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Mean kinetic temperature is widely misused as an averaging trick that makes an excursion disappear. It is a weighted mean designed to reflect the Arrhenius relation, and it is a legitimate tool for a whole storage period. Applying it to a single shipment to argue that a two-day excursion averaged out is not what it is for.

Printing the reasoning rather than only the conclusion is what makes this publication worth the subscription. Please keep doing it even when it makes the pieces longer.

An interlaboratory comparison needs a homogeneous material and a stated assigned value, which is why proficiency schemes in other sectors are run by a body that prepares the material rather than by a participant. Until somebody does that here, these exercises measure agreement rather than accuracy.

You describe blind purchasing as the gold standard. It is the minimum standard. The gold standard is blind purchasing, repeated, with retained samples, published in full including the dull results, and nothing in this market comes close to that.

You describe the services as competitors. From where I sit they are also each other’s only check, because a buyer who disagrees with one result has nowhere to go but another of the four. That is a peculiar market structure and it is worth naming as one.

I keep a bound notebook for submissions: date, molecule, lot, weight sent, courier, tracking, laboratory, report number. It is unglamorous, it takes two minutes an entry, and it has made me the only party in several conversations with an actual record.

Your section on sampling should mention the sealed vial. A laboratory that receives a factory-sealed container and breaks the seal itself can say something about what was in the container. One that receives a decanted aliquot in a plain tube can say something about the tube.

Trial protocols specify what to do after a missed administration, and those instructions are the closest thing to evidence-based guidance available. They are freely readable in the supplementary materials and almost never quoted.

Retitration after an interruption is discussed as though the tolerance acquired during the first course persists. Whether it does is an empirical question and I can find no study addressing it in this class.

You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?

As a prescribing pharmacist I would add one thing about re-titration. The commonest problem I see is not the resumption dose. It is that the patient has a pen left over at the old strength and uses it because it is in the fridge and it cost money. The clinical decision and the economic decision are not the same decision.

A methodological plea. Publish the purchase date, the arrival date and the determination date for every blind result. Without all three, a poor figure cannot be attributed between manufacture, freight and storage, and every party will attribute it wherever suits them.

Consider the cost. A genuinely blind programme means buying material at retail, paying full freight, waiting in the ordinary queue and absorbing the whole expense with no cooperation from the seller. That is why so little of it happens, and the reason is arithmetic rather than principle.

A practical caution about running two methods. If you do not fix in advance what you will do when they disagree, you will find yourself choosing the flattering result after the fact and calling it judgement. Write down the rule before you commission the second determination.

The cheapest orthogonal method is not a second column, it is a change of mobile-phase pH on the column already installed. Formic acid in place of trifluoroacetic acid alters selectivity substantially for basic sequences and costs one equilibration. It is not a full second principle, and it will still separate a co-eluting pair more often than not.

On reference standards, the honest position for most of this market is that there is no pharmacopoeial monograph for the sequence in question, so the standard is a house lot characterised against itself. That is not a scandal, but it should be stated, because a purity figure traceable to a house standard is not traceable in the sense the word usually carries.

On response factors: you say correction requires isolated impurity standards, which is true, but you might mention that charged aerosol and mass-based detection sidestep the problem by responding more uniformly. Neither is exotic any more.

Something your article omits, and it changes where the responsibility sits. Method selection is frequently specified by the customer, not by us. A purchase order arrives asking for a peptide purity run at a stated price and turnaround, and the method that fits those two constraints is the method that runs. We are perfectly willing to develop a longer separation for anybody who wants one, and in eleven years almost nobody has asked.

A supply-side observation. Where somebody has settled on one source for a long commitment, a change in that source’s manufacturing is a change in their arrangement, and it happens without announcement. Your dossier work is the only place I have seen this treated as a continuity question.

Your piece treats maintenance as a single question. In the accounts I read there are at least three: maintaining a weight, maintaining a metabolic marker and maintaining a behaviour. They come apart in practice and are almost always discussed together.

A practical note from a service bench. Sodium and potassium adducts are the commonest reason a first spectrum looks wrong, and they come from the glassware and the water rather than from the sample. Before anybody concludes a peptide is not what it says it is, they should check whether the offset is twenty-two.